Literature DB >> 17347582

The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model.

Peter Hamar1, Gabor Kokeny, Peter Liptak, Jan Krtil, Marcin Adamczak, Kerstin Amann, Eberhard Ritz, Marie-Luise Gross.   

Abstract

BACKGROUND: The blood pressure-independent renoprotective actions of the blockade of the renin-angiotensin and the sympathetic nervous system are well documented, but monotherapies fail to completely abrogate progression. We investigated whether combined inhibition of the two systems provides additive renoprotection.
METHODS: After subtotal nephrectomy (SNX) or sham operation, rats underwent resection of dorsal roots, i.e. rhizotomy or sham rhizotomy. Subsequently, they received tap water or quinapril in drinking water for 16 weeks (n = 18/group). Albuminuria, blood pressure and kidneys were assessed (morphometry, immunohistochemistry).
RESULTS: At the end of the study telemetric blood pressure in SNX was 118 +/- 16 mm Hg, in SNX + rhizotomy 110 +/- 10 mm Hg, in SNX + quinapril 103 +/- 9 mm Hg and in SNX + quinapril + rhizotomy 95 +/- 7 mm Hg. Albuminuria in the respective groups was 169 +/- 75, 86 +/- 45, 15 +/- 23 and 5 +/- 4 mg/24 h. The glomerulosclerosis index was 1.40 +/- 0.6, 0.80 +/- 0.23, 0.37 +/- 0.16 and 0.31 +/- 0.15 (p < 0.001). Only combined intervention caused significant reduction of the glomerular volume and podocyte hypertrophy. The lowest indices for nitrotyrosine, NOS-1 (nNOS), TGF-beta and interstitial collagen were seen with combined interventions (p < 0.05).
CONCLUSION: In angiotensin-converting enzyme inhibitor-treated SNX animals, abrogation of sympathetic overactivity provides additional renoprotection and less nitro-oxidative stress of podocytes than single interventions. The added benefits were partially blood pressure independent. Copyright 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17347582     DOI: 10.1159/000100494

Source DB:  PubMed          Journal:  Nephron Exp Nephrol        ISSN: 1660-2129


  7 in total

1.  Sympathetic nerves and the progression of chronic kidney disease during 5/6 nephrectomy: studies in sympathectomized rats.

Authors:  Robert A Augustyniak; Maria M Picken; David Leonard; Xin J Zhou; Weiguo Zhang; Ronald G Victor
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-06-29       Impact factor: 2.557

2.  Heart rate variability predicts ESRD and CKD-related hospitalization.

Authors:  Daniel J Brotman; Lori D Bash; Rehan Qayyum; Deidra Crews; Eric A Whitsel; Brad C Astor; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2010-07-08       Impact factor: 10.121

Review 3.  Patient Selection for Renal Denervation in Hypertensive Patients: What Makes a Good Candidate?

Authors:  Sheran Li; Jacqueline K Phillips
Journal:  Vasc Health Risk Manag       Date:  2022-05-13

4.  A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy.

Authors:  Yufeng Huang; Wayne A Border; Ling Yu; Jiandong Zhang; Daniel A Lawrence; Nancy A Noble
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

Review 5.  Do beta-blockers combined with RAS inhibitors make sense after all to protect against renal injury?

Authors:  Eberhard Ritz; Lars Christian Rump
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

6.  Oxidative/Nitrative Stress and Inflammation Drive Progression of Doxorubicin-Induced Renal Fibrosis in Rats as Revealed by Comparing a Normal and a Fibrosis-Resistant Rat Strain.

Authors:  Csaba Imre Szalay; Katalin Erdélyi; Gábor Kökény; Enikő Lajtár; Mária Godó; Csaba Révész; Tamás Kaucsár; Norbert Kiss; Márta Sárközy; Tamás Csont; Tibor Krenács; Gábor Szénási; Pál Pacher; Péter Hamar
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

7.  Endovascular renal denervation: a novel sympatholytic with relevance to chronic kidney disease.

Authors:  Neil A Hoye; James C Baldi; Tracey L Putt; John B Schollum; Gerard T Wilkins; Robert J Walker
Journal:  Clin Kidney J       Date:  2013-11-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.